Anticoagulation Management Flashcards
7 cards from real BCACP practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 Anticoagulation Management flashcards as text
Which DOAC has the lowest proportion of renal elimination (~27%), making it most suitable in patients with chronic kidney disease?
Answer: Apixaban
Apixaban has approximately 27% renal elimination, the lowest among the four approved DOACs, compared to dabigatran (~80%), making it most favorable in CKD patients.
Idarucizumab (Praxbind) is the FDA-approved specific reversal agent for which anticoagulant?
Answer: Dabigatran
Idarucizumab is a humanized monoclonal antibody fragment that specifically binds and neutralizes dabigatran's anticoagulant effect.
Andexanet alfa (Andexxa) is FDA-approved for reversal of which anticoagulants in life-threatening bleeding?
Answer: Rivaroxaban and apixaban
Andexanet alfa is a modified recombinant Factor Xa decoy protein approved for reversing rivaroxaban and apixaban (both Factor Xa inhibitors) in life-threatening bleeding.
According to AHA/ACC guidelines, oral anticoagulation is RECOMMENDED (not merely considered) for males with nonvalvular atrial fibrillation when their CHA2DS2-VASc score reaches:
Answer: 2 or greater
AHA/ACC guidelines recommend oral anticoagulation for males with nonvalvular AF and CHA2DS2-VASc score of 2 or greater; a score of 1 makes anticoagulation reasonable but not definitively recommended.
Which anticoagulant regimen is now preferred over LMWH for cancer-associated thrombosis in patients without high gastrointestinal or genitourinary bleeding risk?
Answer: Apixaban or rivaroxaban (direct oral anticoagulants)
Updated ISTH and ASCO guidelines recommend DOACs (apixaban or rivaroxaban) over LMWH as preferred therapy for cancer-associated thrombosis in appropriate patients.
A patient taking apixaban requires emergent surgery within 8 hours after a serious fall. Which is the most appropriate reversal strategy?
Answer: Andexanet alfa per weight-based dosing protocol
Andexanet alfa is the FDA-approved specific reversal agent for apixaban and rivaroxaban, indicated for life-threatening or urgent surgical bleeding situations.
All DOACs are contraindicated for stroke prevention in atrial fibrillation in patients with which of the following conditions?
Answer: Mechanical prosthetic heart valve
All DOACs are contraindicated in patients with mechanical prosthetic heart valves, as clinical trials demonstrated significantly higher rates of stroke and bleeding compared to warfarin.